trending Market Intelligence /marketintelligence/en/news-insights/trending/Lzmz0ZnVhlPcAwqx7ztKqw2 content esgSubNav
In This List

Retrophin names CEO

Blog

Baird Research is Now Exclusively Available in S&P Global’s Aftermarket Research Collection

Blog

Japan M&A By the Numbers: Q4 2023

Blog

Essential IR Insights Newsletter Fall - 2023

Case Study

A Corporation Clearly Pinpoints Activist Investor Activity


Retrophin names CEO

Retrophin Inc. appointed Eric Dube president and CEO, effective Jan. 4.

Prior to joining Retrophin, Dube was president of North America at ViiV Healthcare, a GlaxoSmithKline PLC unit.

Dube succeeds Stephen Aselage, who is retiring. Aselage, who has been CEO since 2014, will continue to serve on Retrophin's board.

Dube will also serve on the board of the San Diego-based biopharmaceutical company, which develops therapies for rare diseases.